Premium
Development of Cytodifferentiating Agents for Cancer Chemotherapy
Author(s) -
Breslow Ronald,
Belvedere Sandro,
Gershell Leland
Publication year - 2000
Publication title -
helvetica chimica acta
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.74
H-Index - 82
eISSN - 1522-2675
pISSN - 0018-019X
DOI - 10.1002/1522-2675(20000809)83:8<1685::aid-hlca1685>3.0.co;2-4
Subject(s) - chemistry , histone deacetylase , potency , cancer cell , histone deacetylase inhibitor , cancer chemotherapy , toxicity , cancer , chemotherapy , pharmacology , cancer research , histone , biochemistry , combinatorial chemistry , in vitro , medicine , organic chemistry , dna , biology
Starting from the accidental observation that dimethylsulfoxide induces the differentiation of murine erythroleukemia cells, compounds have been designed with increasing potency in transforming this and other cancer‐cell types. The target for the most effective of the new compounds has been identified as histone deacetylase, whose natural substrate maps well onto the structures of the particularly effective compounds. Preclinical and early clinical studies suggest that the best of the compounds are promising anticancer agents without excessive toxicity.